Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
- histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1: Note: Cohort closed to further enrolment) or Squamous Cell Carcinoma head and neck cancer (cohort 2) or Squamous Cell Carcinoma other than HNSCC (cohort 3) for which there is no curative therapy available.
- tumor that carries a missense HRAS mutation ith a variant allele frequency (VAF) > 20%.
- Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status
- Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.
- At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
- ECOG PS 0 or 1
- Acceptable liver function
- Acceptable renal function
- Acceptable hematologic status • Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥ 35%) may be enrolled despite a serum albumin < 3.5 g/dL.
- Prior treatment with an FTase inhibitor
- History of relevant coronary heart disease or myocardial infarction within last 3 years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or serious cardiac arrhythmia requiring medication except atrial fibrillation.
- Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day
- - Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose
- Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C
This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subjects with information available on tumor HRAS status previously generated are eligible. All subjects must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a retrospective testing of HRAS gene status at a central facility. Subjects will be enrolled into three nonrandomized cohorts: - Cohort 1: Malignant thyroid tumors with HRAS mutations (cohort is closed). - Cohort 2: Squamous Cell Carcinoma Head and Neck Cancer with HRAS mutations. - Cohort 3: Squamous Cell Carcinoma (SCC) with HRAS mutations other than HNSCC
Trial Phase Phase II
Trial Type Treatment
Kura Oncology, Inc.
- Primary ID KO-TIP-001
- Secondary IDs NCI-2015-01835, NCI-2015-00949
- Clinicaltrials.gov ID NCT02383927